{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-064744","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2026-06-03T20:25:25+00:00","discovered_at":"2026-06-03T20:26:01.325349+00:00","generated_at":"2026-06-03T20:51:28.260196+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cadrenal Therapeutics CFO Matthew Szot leaves; CEO Quang Pham takes interim CFO role","bullets":["CFO Matthew K. Szot mutually agreed to step down effective May 28, 2026.","CEO Quang X. Pham appointed interim CFO and interim principal accounting officer.","Company is conducting a search for a permanent CFO to replace Szot.","Severance includes $365,806 severance, $237,903 FY2026 target bonus, and accelerated option vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-064744","json":"https://secwatch.observer/filing/0001213900-26-064744.json","markdown":"https://secwatch.observer/filing/0001213900-26-064744.md","text":"https://secwatch.observer/filing/0001213900-26-064744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026064744/0001213900-26-064744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026064744/ea0293458-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T20:51:28.260196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d4d33af2c","claim":"Matthew K. Szot changed role as Chief Financial Officer at Cadrenal Therapeutics, Inc..","evidence_excerpt":"On May 28, 2026, Cadrenal Therapeutics, Inc. (the \"Company\") and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026064744/0001213900-26-064744-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"mutually agreed to his transition from the role"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"a0649cd035","claim":"Quang X. Pham was appointed as interim Chief Financial Officer and interim Principal Accounting Officer at Cadrenal Therapeutics, Inc..","evidence_excerpt":"Effective immediately after Mr. Szot's termination, the Company appointed Quang X. Pham, its Chief Executive Officer, as interim Chief Financial Officer and interim Principal Accounting Officer, to serve until a permanent Chief Financial Officer is appointed.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026064744/0001213900-26-064744-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Financial Officer and interim Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}